“Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial.”, Lancet, vol. 391, no. 10118, pp. 309-318, 2018.
, “Comparison of Methods for Alcohol and Drug Screening in Primary Care Clinics”, JAMA Network Open, vol. 4, no. 5, p. e2110721, 2021.
, “Successful Implementation of Substance Use Screening in Rural Federally-Qualified Health Centers Identified High Rates of Unhealthy Alcohol, Cannabis, and Tobacco Use”, in The College on Problems of Drug Dependence (CPDD), Minneapolis, MN, 2022.
,